Iatrogenic factors of Helicobacter pylori eradication failure: lessons from the frontline

References

• Robinson K, Atherton JC. The spectrum of Helicobacter-mediated diseases. Annu Rev Pathol. 2021;16:123–144.
   PubMed Web of Science ®Google Scholar
• Boltin D, Niv Y, Schütte K, et al. Review: Helicobacter pylori and non-malignant upper gastrointestinal diseases. Helicobacter. 2019;24(Suppl 1):e12637.
   PubMedGoogle Scholar
• Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(3):435–445.
   PubMed Web of Science ®Google Scholar
• Ford AC, Gurusamy KS, Delaney B, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016;4(4):Cd003840.
   PubMedGoogle Scholar
• Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61(4):507–513.
   PubMed Web of Science ®Google Scholar
• Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion. 2011;83(4):253–260.
   PubMed Web of Science ®Google Scholar
• Yan L, Chen Y, Chen F, et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology. 2022;163(1):154–162.e153.
   PubMed Web of Science ®Google Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.e14.
   PubMed Web of Science ®Google Scholar
• Liu WZ, Xie Y, Lu H, et al. Fifth Chinese National consensus report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2):e12475.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:1–39.
   Web of Science ®Google Scholar
• Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019–1026.
   PubMed Web of Science ®Google Scholar
• Zou Y, Qian X, Liu X, et al. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12714.
   PubMed Web of Science ®Google Scholar
• Song C, Xie C, Zhu Y, et al. Management of Helicobacter pylori infection by clinicians: a nationwide survey in a developing country. Helicobacter. 2019;24(6):e12656.
   PubMed Web of Science ®Google Scholar
• Song Z, Chen Y, Lu H, et al. Diagnosis and treatment of Helicobacter pylori infection by physicians in China: a nationwide cross-sectional study. Helicobacter. 2022;27(3):e12889.
   PubMed Web of Science ®Google Scholar
• Nyssen OP, Vaira D, Tepes B, et al. Room for improvement in the treatment of Helicobacter pylori infection: lessons from the European registry on H. pylori management (Hp-EuReg). J Clin Gastroenterol. 2022;56(2):e98–e108.
   PubMed Web of Science ®Google Scholar
• Liu DS, Wang YH, Zeng ZR, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect. 2018;24(7):780.e785–780.e788.
   Web of Science ®Google Scholar
• Nyssen OP, Á P-A, Tepes B, et al. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: experience from the European registry on H pylori management (Hp-EuReg). Helicobacter. 2020;25(3):e12686.
   PubMed Web of Science ®Google Scholar
• Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870–878.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylorieradication therapies. Helicobacter. 2017;22(4):e12392.
   Web of Science ®Google Scholar
• Shi X, Wang C, Meng F, et al. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgrad Med. 2022;134:668–674.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;(12):Cd008337.
   PubMed Web of Science ®Google Scholar
• Li H, Liang X, Chen Q, et al. Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study. Scand J Gastroenterol. 2018;53(2):130–133.
   PubMed Web of Science ®Google Scholar
• Scida S, Miraglia C, Tursi A, et al. The search for optimal interval after failure of Helicobacter pylori cure: aiming to rescue therapy. Helicobacter. 2018;23:75.
   Web of Science ®Google Scholar
• Kotilea K, Mekhael J, Salame A, et al. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22(4):e12383.
   Web of Science ®Google Scholar
• Shah SC, Tepler A, Chung CP, et al. Host genetic determinants associated with Helicobacter pylori eradication treatment failure: a systematic review and meta-analysis. Gastroenterology. 2021;161(5):1443–1459.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/florence consensus report. Gut. 2017;66(1):6–30.
   PubMed Web of Science ®Google Scholar
• McNicholl AG, Amador J, Ricote M, et al. Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: information, attitudes, and decisions. Helicobacter. 2019;24(4):e12593.
   PubMed Web of Science ®Google Scholar
• Liu DS, Wang YH, Zhu ZH, et al. Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations. Antimicrob Resist Infect Control. 2019;8:192.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Zhang Z, Wang J, et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China. Am J Cancer Res. 2021;11(10):5027–5037.
   PubMed Web of Science ®Google Scholar
• Wang YH, Wang FF, Gong XL, et al. Genotype profiles of Helicobacter pylori from gastric biopsies and strains with antimicrobial-induced resistance. Therap Adv Gastroenterol. 2020;13:1756284820952596.
   Web of Science ®Google Scholar
• Cheon JH, Kim SG, Kim JM, et al. Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility. J Gastroenterol Hepatol. 2006;21(10):1590–1595.
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–1153.
   PubMed Web of Science ®Google Scholar
• Ke H, Li J, Lu B, et al. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy. Helicobacter. 2021;26(1):e12768.
   PubMedGoogle Scholar
• Villoria A, Garcia P, Calvet X, et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28(7):868–877.
   PubMed Web of Science ®Google Scholar
• Martinucci I, Blandizzi C, Bodini G, et al. Vonoprazan fumarate for the management of acid-related diseases. Expert Opin Pharmacother. 2017;18(11):1145–1152.
   PubMed Web of Science ®Google Scholar
• Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:2217–2228.
   PubMed Web of Science ®Google Scholar
• Hong J, Shu X, Liu D, et al. Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial. J Antimicrob Chemother. 2016;71(8):2280–2285.
   PubMed Web of Science ®Google Scholar
• Long X, Chen Q, Yu L, et al. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter. 2018;23(3):e12485.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu S. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients. Singapore Med J. 2012;53(4):273–276.
   PubMed Web of Science ®Google Scholar
• Calvet X, García N, López T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14(5):603–609.
   PubMed Web of Science ®Google Scholar
• Calvet X. Dealing with uncertainty in the treatment of Helicobacter pylori. Ther Adv Chronic Dis. 2018;9(4):93–102.
   PubMed Web of Science ®Google Scholar
• Graham DY, Dore MP. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016;14(6):577–585.
   PubMed Web of Science ®Google Scholar